European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

Recording: Is immune therapy changing the way we think about early bladder cancer?

Early bladder cancer, including muscle invasive and non-muscle invasive disease is prevalent and a huge cancer healthcare issue.

Published Thu, 4 Jul 2019
Recorded WebinarOncologyBladder CancerRadiotherapy
OrganiserEuropean School of Urology (ESU)
CMENot approved
DurationApprox. 40 minutes

Multimodality treatments have been employed, including chemotherapy, BCG, surgery and radiotherapy.

Aggressive early disease remains lethal. The immune checkpoint inhibitors have changed treatment of metastatic disease. The biology and initial data suggests they could be even more active in early disease. The data supporting this is discussed in this recorded webinar.

Presenter: Dr. Thomas Powles

Contact our organiser

European School of Urology (ESU)

Email:  educationonline@uroweb.org

Share this event

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer